The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections.

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

In a bold step toward global health justice, Ugandan biotech company DEI BioPharma has announced it will begin manufacturing ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

Learn more about lenacapavir, the most effective HIV treatment and prevention drug, and how its cost could cause a setback.

Gilead’s HIV treatment trials involving GS-1720 and GS-4182 have been put on clinical hold by the Food and Drug Administration.

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.

"We don't want to shut these doors, we want to make sure they stay open and we can help as many people as we can".